MY189774A - Atropine-containing aqueous composition - Google Patents

Atropine-containing aqueous composition

Info

Publication number
MY189774A
MY189774A MYPI2018001914A MYPI2018001914A MY189774A MY 189774 A MY189774 A MY 189774A MY PI2018001914 A MYPI2018001914 A MY PI2018001914A MY PI2018001914 A MYPI2018001914 A MY PI2018001914A MY 189774 A MY189774 A MY 189774A
Authority
MY
Malaysia
Prior art keywords
buffer
atropine
aqueous composition
containing aqueous
aminocarboxylate
Prior art date
Application number
MYPI2018001914A
Other languages
English (en)
Inventor
Donald Tan
Roger Beuerman
Hiroyuki Asada
Kyohei Takahashi
Koji Sakanaka
Takashi Morimoto
Toyomi Fujisawa
Original Assignee
Univ Nanyang Tech
Santen Pharmaceutical Co Ltd
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60411416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY189774(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Nanyang Tech, Santen Pharmaceutical Co Ltd, Singapore Health Serv Pte Ltd filed Critical Univ Nanyang Tech
Publication of MY189774A publication Critical patent/MY189774A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
MYPI2018001914A 2016-05-25 2017-05-24 Atropine-containing aqueous composition MY189774A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201604200P 2016-05-25
PCT/JP2017/019423 WO2017204262A1 (en) 2016-05-25 2017-05-24 Atropine-containing aqueous composition

Publications (1)

Publication Number Publication Date
MY189774A true MY189774A (en) 2022-03-04

Family

ID=60411416

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018001914A MY189774A (en) 2016-05-25 2017-05-24 Atropine-containing aqueous composition

Country Status (15)

Country Link
US (2) US20210267885A1 (enExample)
EP (2) EP4112055A1 (enExample)
JP (6) JP6590860B2 (enExample)
KR (4) KR20250067951A (enExample)
CN (3) CN117205209A (enExample)
AR (1) AR108591A1 (enExample)
CA (1) CA3023149C (enExample)
EA (1) EA201892703A1 (enExample)
ES (1) ES2929368T3 (enExample)
MY (1) MY189774A (enExample)
PH (1) PH12018502421A1 (enExample)
SG (1) SG11201809822SA (enExample)
TW (3) TWI849355B (enExample)
UA (1) UA126195C2 (enExample)
WO (1) WO2017204262A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
WO2018154440A1 (en) * 2017-02-21 2018-08-30 Singapore Health Services Pte Ltd Composition and method for preventing or delaying onset of myopia comprising atropine
MX392558B (es) 2017-05-11 2025-03-24 Vyluma Inc Composición oftálmica líquida estable, que comprende una solución acuosa con un tampón, un agente de tonicidad, un quelante, un modificador de la viscosidad y atropina; y el uso de la misma para el tratamiento de la miopía.
CN109157503B (zh) * 2018-09-25 2019-08-16 沈阳兴齐眼药股份有限公司 防治nitm的药物组合物及其医药用途
CN110934816B (zh) * 2018-09-25 2022-04-08 沈阳兴齐眼科医院有限公司 一种提高低浓度阿托品眼用制剂稳定性的方法
EP3701938B8 (en) 2019-03-01 2024-02-21 Medivis S.R.L. Ophthalmic formulations based on atropine
CN114302726A (zh) * 2020-08-04 2022-04-08 参天制药株式会社 用于治疗近视、预防近视及/或抑制近视发展的药剂
AU2021362374A1 (en) * 2020-10-14 2023-05-25 Santen Pharmaceutical Co., Ltd. Stable pharmaceutical composition
AU2021368138A1 (en) 2020-11-02 2023-06-22 Trethera Corporation Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof
WO2022130337A1 (en) * 2020-12-17 2022-06-23 Sun Pharmaceutical Industries Limited An aqueous sterile solution of atropine for ophthalmic use
EP4088714A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
EP4088713A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
US20230120997A1 (en) * 2021-10-18 2023-04-20 Ocular Science, Inc. Compositions and methods for myopia control and orthokeratology lenses treatment
CN114129511A (zh) * 2021-12-07 2022-03-04 河南润弘制药股份有限公司 一种具有改进稳定性的硫酸阿托品注射液
AU2023337098A1 (en) * 2022-09-11 2024-10-03 Alcon Inc. Aqueous pharmaceutical compositions comprising benzyl atropine and uses thereof
JP7665073B1 (ja) 2024-04-05 2025-04-18 ロート製薬株式会社 容器に収容してなる眼科用組成物
JP7723851B1 (ja) * 2024-11-22 2025-08-14 参天製薬株式会社 アトロピン含有水性医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617508B2 (ja) * 1988-02-05 1997-06-04 エーザイ株式会社 安定なジフェンヒドラミン含有水溶液
JP3166002B2 (ja) * 1997-01-27 2001-05-14 日本車輌製造株式会社 自動車の洗浄装置
US20030096831A1 (en) 2000-01-18 2003-05-22 Stone Richard A. Ocular growth and nicotinic antagonists
EP1397132A4 (en) * 2001-05-25 2006-12-13 Valley Forge Pharmaceuticals I OPHTHALMIC PIRENZEPINE GEL
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法
WO2008144065A1 (en) * 2007-05-21 2008-11-27 Neuroptix Corporation Ophthalmic formulations of amyloid- contrast agents and methods of use thereof
CN101327216A (zh) * 2007-06-22 2008-12-24 肖正连 一种硫酸阿托品眼用即型凝胶
WO2012161655A1 (en) * 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
US20160009705A1 (en) * 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
JP2017102939A (ja) * 2016-12-26 2017-06-08 株式会社プロフィールド オーサリング装置、オーサリング方法、およびプログラム
MX392558B (es) 2017-05-11 2025-03-24 Vyluma Inc Composición oftálmica líquida estable, que comprende una solución acuosa con un tampón, un agente de tonicidad, un quelante, un modificador de la viscosidad y atropina; y el uso de la misma para el tratamiento de la miopía.

Also Published As

Publication number Publication date
JP2023058574A (ja) 2023-04-25
JP2025084921A (ja) 2025-06-03
TW202325296A (zh) 2023-07-01
EP3463360A4 (en) 2020-01-29
CA3023149C (en) 2024-07-02
JP6590860B2 (ja) 2019-10-16
KR20230141882A (ko) 2023-10-10
TWI849355B (zh) 2024-07-21
EA201892703A1 (ru) 2019-04-30
KR102804061B1 (ko) 2025-05-07
KR102580933B1 (ko) 2023-09-19
AR108591A1 (es) 2018-09-05
TWI791438B (zh) 2023-02-11
CA3023149A1 (en) 2017-11-30
PH12018502421A1 (en) 2019-09-30
JP2020007356A (ja) 2020-01-16
JP7224390B2 (ja) 2023-02-17
JP2025176149A (ja) 2025-12-03
EP3463360A1 (en) 2019-04-10
EP3463360B1 (en) 2022-08-31
JP2021120404A (ja) 2021-08-19
TWI874894B (zh) 2025-03-01
SG11201809822SA (en) 2018-12-28
JP6886502B2 (ja) 2021-06-16
TW201808289A (zh) 2018-03-16
KR20220154842A (ko) 2022-11-22
KR20190013877A (ko) 2019-02-11
UA126195C2 (uk) 2022-08-31
TW202206070A (zh) 2022-02-16
JP2018021007A (ja) 2018-02-08
WO2017204262A1 (en) 2017-11-30
EP4112055A1 (en) 2023-01-04
KR20250067951A (ko) 2025-05-15
CN117205209A (zh) 2023-12-12
ES2929368T3 (es) 2022-11-28
CN117205210A (zh) 2023-12-12
CN109310687B (zh) 2023-10-20
US20210267885A1 (en) 2021-09-02
US20240307305A1 (en) 2024-09-19
CN109310687A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
CA3023149C (en) AQUEOUS COMPOSITION CONTAINING ATROPINE
MX2022012110A (es) Sistemas crispr clase ii tipo ii.
WO2019014395A8 (en) GENERATION OF WATER-SOLUBLE CANNABINOID COMPOUNDS IN PLANT CELL SUSPENSION YEAST AND CROPS AND MATERIAL COMPOSITIONS
WO2018175636A3 (en) Compositions and methods for immunooncology
WO2018006074A3 (en) Compounds and methods for modulating rna function
MY198483A (en) Latex composition
MX2017008937A (es) Carbonato de calcio tratado en la superficie con estabilidad mejorada en ambientes con un ph de 4.5 a 7.
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
MX2020002885A (es) Derivados de galnac.
PH12017500286B1 (en) Lithium-containing calcium aluminate phosphate cement admixtures
EP4309732A3 (en) Modulators of pcsk9 expression
JOP20200323A1 (ar) طرق لتصنيع تركيبات الأحماض الأمينية
UY35770A (es) ?material micronizado que contiene carbonato alcalinotérreo para regular el ph de un suelo?.
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
WO2019013532A3 (ko) 아세토하이드록시산 신타아제 변이체, 이를 포함하는 미생물 또는 이를 이용하는 l-분지쇄 아미노산 생산 방법
PH12016502386A1 (en) Oral care compositions
PH12020551154A1 (en) Method for suppressing discoloration of external composition containing adenosine phosphate and tranexamic acid
ZA202001315B (en) Aqueous spray composition
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
PH12019501977B1 (en) Additive composition for ground improvement
GB2560286A (en) Nanofibril cellulose additive
AU2018313492A8 (en) Beverage
PH12018501957A1 (en) Oral care composition
MX2019003245A (es) Sistemas multifuncionales de un solo componente y metodos de acidificacion de arenisca.
AU2017244688A1 (en) Amorphizing agent, Amorphous composition comprising Amorphizing agent and utilization thereof